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Abstract
Amyloidosis represents a heterogeneous group of disorders caused by 
amyloid fibril deposition in the extracellular space in different organs. Among 
the many types of amyloidosis cardiac involvement occurs almost exclusively 
with immunoglobulin light chain amyloidosis (AL amyloidosis) or transthyretin 
amyloidosis (ATTR amyloidosis). When present cardiac amyloidosis (CA) has a 
significant impact on disease prognosis. The typical clinical presentation in CA is 
that of a restrictive cardiomyopathy. Clinical suspicion of CA is based on clinical, 
laboratory and electrocardiographic findings. The diagnosis is confirmed using 
echocardiography, cardiac magnetic resonance imaging, biopsy, and/or bone 
scintigraphy. A precise definition of amyloidosis type is essential for choosing the 
specific treatment for this condition. Treatment of CA has two components: general 
treatment of congestive HF, and specific treatment of the underlying protein 
misfolding disorder.
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1. Introduction
All types of amyloidosis involve deposition of amyloidogenic protein, composed 
of low molecular weight subunits, most of which circulate as plasma components. 
The amyloid deposits are formed by subunit proteins which originate from soluble 
precursors. These proteins have undergone conformational changes that generated 
an antiparallel beta-pleated sheet.
There are more than 30 precursor proteins that can form deposits in the 
extracellular space and can generate progressive organ dysfunction.
The majority of cases of amyloidosis are caused by 3 subtypes: the most common 
form, which accounts for approximately 70% of all cases is AL amyloidosis, due to 
the deposition of misfolded immunoglobulin light chains. The other two forms with 
increased prevalence are ATTR amyloidosis caused by deposition of transthyretin 
either as wild-type (ATTRwt) form, or mutated/variant (ATTRv) [1].
CA is a myocardial infiltrative disease due to amyloid fibril deposition in 
the extracellular space of the heart. The infiltrative process results in increased 
thickness of the left ventricular wall, diastolic dysfunction and HF.
Until about a decade ago amyloidosis used to be considered a rare condition, 
managed primarily by hematologists, neurologists and nephrologists. CA used to be 
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diagnosed late in the evolution of the disease, with negative impact on prognosis of 
these patients. In the last few years there has been and increased emphasis on early 
diagnosis on optimization of screening and diagnosis of CA. The reason for this is 
the advent of targeted therapies, which showed increased efficacy in treating CA if 
they are applied early in the course of the disease [2].
Systemic forms of amyloidosis affecting the heart, are mainly AL, ATTRwt, and 
some forms of ATTRv amyloidosis [1].
2. Pathophysiology and epidemiology of CA
The pathophysiology of CA is complex. Amyloid infiltration of the heart leads to 
a decrease in ventricular compliance. This in turn creates the premises for diastolic 
dysfunction. The decrease in ventricular compliance is associated with an elevation 
in ventricular filling pressures. Backward transmission of high filling pressures 
results in bi-atrial dilatation and stasis.
AL amyloidosis is usually caused by a small clonal B cell or plasma cell 
population, with about 10% of patients having multiple myeloma [3]. From a 
pathophysiological standpoint there is interstitial deposition of immunoglobulin 
light chains, as well as direct toxicity on the myocytes caused by the free light 
chains. These chains can induce lysosomal dysfunction, oxidative stress, apop-
tosis, and dysregulation of MAP kinase signaling transduction pathways as well 
as autophagy [4]. The amount of cardiac involvement independently predicts 
mortality [4].
Transthyretin (TTR), which is a transport protein for retinol and thyroid 
hormone synthesized by the liver, can form amyloid fibrils when it dissociates from 
tetramers into monomers. The destabilization tetramers with accumulation of TTR 
monomers can result from gene mutations in the TTR gene (ATTRv) or are the 
result of age-related processes (ATTRwt) [4].
The pathophysiology of CA is complex. Amyloid infiltration of the heart leads to 
a decrease in ventricular compliance. This in turn creates the premises for diastolic 
dysfunction. The decrease in ventricular compliance is associated with an elevation 
in ventricular filling pressures. Backward transmission of high filling pressures 
results in bi-atrial dilatation and stasis.
Detailed information regarding the epidemiology of CA is lacking. Gilstrap et 
al., in a study published in 2019, found a prevalence rate of CA among Medicare 
beneficiaries of 8–17 per 100,000 person-years. The incidence rate in the same 
study was 18–55 per 100,000 person-years [5]. The prevalence of AL amyloidosis 
has increased 2.6-fold in the United States between from 15.5 cases per million in 
2007 to 40.5 in 2015 [6].
Cardiac involvement in AL amyloidosis is a major determinant of prognosis, 
with mean survival time is only about 6 months without treatment in cases with 
advanced cardiac disease and HF [7]. The median overall survival is extended to 
>5 years if modern treatment strategies are used [1].
3. Clinical manifestations
The clinical presentation of patients with amyloidosis is heterogeneous and 
nonspecific and, varies depending on the degree of organ involvement. The onset of 
symptoms depends on the type of amyloidosis.
Amyloid infiltration of the heart can generate symptoms and signs that are 




Lower extremity edema is a nonspecific clinical manifestation, which is common 
in different conditions associated with heart failure (HF). It can be associated with 
the elevation of jugular venous pressure, pleural effusion, ascites, pain in the right 
hypochondriac region caused by liver congestion, dyspnea at exertion or at rest and 
orthopnea. These symptoms are related predominantly to right ventricular failure 
and restrictive cardiomyopathy, which is one of the most common forms of presen-
tation in CA [8].
Another symptom that can occur in CA is presyncope or syncope consequent to 
bradyarrhythmias or high-degree/complete atrioventricular block. Loss of con-
sciousness is often present in AL amyloidosis and in some cases can have combined 
etiology [9]. Furthermore, hypotension induced by autonomic neuropathy may lead 
to syncope in patients with amyloidosis.
Sometimes, patients complain of palpitations which occur in the setting of 
atrial fibrillation (AF) due to the infiltration of the atrium with amyloid deposits 
or by the dilated atrium secondary to restrictive cardiomyopathy. This is the most 
common described arrhythmia, found in 10–15% of the patients [10]. Ventricular 
tachyarrhythmias can occur in advanced stages of the cardiomyopathy, however 
sudden cardiac death often due to electromechanical dissociation [9].
In advanced forms of CA with systolic dysfunction, the patient can exhibit 
signs and symptoms of low cardiac output such as fatigue, dizziness, weakness, 
hypotension, delayed capillary refill and decreased pressure of pulse wave.
Angina or myocardial infarction, rare manifestations of CA, may develop as a 
cause of microvascular dysfunction or amyloid deposits in the coronary arteries 
[8]. However, an in vitro experiment performed by Liao R. et al. showed that 
amyloidogenic light chains may have a direct toxic effect on cardiac myocytes 
[11] and it can explain why patients with AL amyloidosis have poorer quality 
of life than patients with ATTR amyloidosis with the same degree of cardiac 
involvement.
Extracardiac organ involvement leads to a plethora of other signs and symptoms 
in amyloidosis. Because of the variety of the manifestations such as nephrotic 
syndrome, gastrointestinal symptoms, pulmonary disease, bleeding diathesis, 
macroglossia, purpura, musculoskeletal abnormalities, carpal tunnel syndrome, the 
diagnosis is often delayed [12].
Due to the multisystemic involvement of this pathology, it is worth to 
mention that pulmonary disease is seen in about 50% of cases. Pulmonary 
amyloidosis has different patterns such as diffuse alveolar septal involvement, 
tracheobronchial and nodular parenchymal amyloidosis. Clinical manifestations 
of pulmonary amyloidosis could be misinterpreted because of the nonspecific 
signs and symptoms such as dyspnea at exertion, weight loss or productive 
cough. Because of the poor prognosis of these patients, as we can see in CA too, 
pulmonary involvement must be searched during the work-up and specific treat-
ment should be initiated.
Given these clinical considerations, CA should be considered in the differen-
tial diagnosis in a patient with HF, unexplained left ventricular hypertrophy and 
preserved ejection fraction.
4. Laboratory and electrocardiographic findings in CA
There is no specific serum biomarker for the ATTR subtype. In the case of 
AL amyloidosis however, blood screening tests are available and these include 
electrophoresis and immunofixation of serum and urine proteins, as well as 
quantification of immunoglobulin free light chain levels with evaluation of the 
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kappa - lambda ratio [13]. Due to the possible presence of a monoclonal gam-
mopathy of undetermined significance (MGUS) in up to 5% of the general popu-
lation aged >65 years, positive laboratory findings need to be carefully evaluated 
[13]. In the meantime, the cardiac amyloidosis’ ATTR subtype may coexist with 
MGUS and needs to be differentiated from the AL subtype by seeking evidence 
of amyloid infiltration in affected organs with identification of the precursor 
protein [13].
Amyloid fibrils deposition in the myocardium is often correlated with the onset 
of arrhythmias and conduction abnormalities, consequently highlighting the key 
role of the electrocardiogram (ECG) in the diagnostic assessment [14]. One of the 
ECG findings is the presence of diffuse low voltage in the limb and/or precordial 
leads [15]. Even if this ECG finding is not very sensitive and it generally occurs 
only in late the stages of the disease, it is common, specific and has prognostic 
signficance in patients with CA [16]. In order to increase the diagnostic sensitiv-
ity, a low-voltage-to-mass ratio assessment was suggested (given the discordance 
between the low voltage on the ECG and the left ventricular hypertrophy on cardiac 
imaging) (Figure 1) [16].
Another important finding on the ECG, which is present in up to 70% of 
these patients, is the pseudoinfarction pattern which consists of pathologic Q 
or QS waves in any two consecutive leads, but without any history of infarction 
and without wall motion abnormalities [16]. As previously mentioned, patients 
with CA also tend to develop, as the disease progresses, arrhythmias which 
range from brady- and tachyarrhythmias or sudden cardiac death [17]. The most 
common arrhythmia noted in CA is AF (up to 70% of patients), but ventricular 
arrhythmias such as premature ventricular beats or ventricular tachycardia can 
also occur [18]. Conduction disease is also common and appears to be more 
frequent in the wtATTR subtype. This last condition can require implant of a 
pacemaker [18].
Figure 1. 




5. Diagnostic suspicion of CA
In the past CA used to be underdiagnosed, given its nonspecific symptoms 
and because it was thought to be a rare condition. In order to improve diagnostic 
specificity and sensitivity different “red flag” signs can be used to raise the clinical 
suspicion and allow an early diagnosis [16].
ATTR amyloidosis which consequentially determines cardiac amyloid infiltra-
tion is usually preceded years before onset by various clinical entities such as: 
carpal tunnel syndrome, lumbar spinal stenosis, and biceps tendon rupture [16]. 
Moreover, ATTR is also often associated with sensoriomotor polyneuropathy, 
autonomic dysfunction as orthostatic hypotension, erectile dysfunction, gastroin-
testinal motility disorders or urinary retention [16].
Even if not sensitive, macroglossia and periorbital purpura are specific signs for 
the AL amyloidosis and are rare seen in ATTR subtype. Other “red flags” for AL 
subtype include hepatomegaly and peripheral neuropathy, but these are neither 
sensitive, nor specific for this condition. Also, when facing patients with undiffer-
entiated cardiac hypertrophy and nephrotic proteinuria, AL amyloidosis should be 
considered as a possible diagnosis [16].
6. Echocardiography in CA
Transthoracic echocardiogram is the most common non-invasive imaging 
tool used in patients with suspected or confirmed amyloidosis. In 1975 Chew et 
al. described for the first time the echocardiographic appearance of CA, based on 
M-mode tracings. The features seen were: normal diastolic size of the left ventricle, 
increased systolic dimension and pericardial effusion; given these findings‚ the 
term” stiff heart” was chosen in these patients [19, 20].
Later on more echocardiographic features were added to the amyloid phenotype: 
symmetric thickness of the left ventricular wall in patients with no history of hyper-
tension or aortic valvular abnormalities, hypokinetic interventricular septum and 
posterior left ventricular wall with decreased systolic thickening, normal or small left 
ventricle cavity, increased thickness of the right ventricular anterior wall, dilated left 
atrium, a decrease of the E-F slope (given reduced ventricular compliance) [19, 21–23].
6.1 Two-dimensional echocardiography
The development of two-dimensional echocardiography offered the posibility 
to describe further the amyloid phenotype [20]. Some defining features of CA are 
represented by left ventricular hypertrophy with a normal/reduced cavity volume, 
increased thickness of the right ventricular wall and the valves (especially aortic 
and mitral valves), and bi-atrial enlargement (Figures 2 and 3) [24, 25].
Concerning the left ventricular wall thickness, it has a different pattern depend-
ing on the amyloidosis type: symmetrical in AL and asymmetrical in ATTR [26]. 
The presence of extracellular amyloid deposits gives the myocardium a „granular 
sparkling” appearance, better visualized at the interventricular septum [27]. A 
small pericardial effusion or dilated inferior vena cava are often observed as signs of 
a restrictive filling pattern [28].
6.2 Doppler
In the 80s, Doppler ultrasound offered new possibilities to characterize the 
heart’s function and structure, providing a more accurate diagnosis, and the 
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diastolic dysfunction became a main feature of CA. First studies, performed by 
Klein et al. revealed that in early stages, when the parietal thickness of the left 
ventricle is 12-15 mm, there is an abnormal relaxation with a reduced early filling 
velocity, elevated late velocity, reduced early to late velocitsy ratio and longer 
isovolumic relaxation time. Contrary to this, in late-stage CA associated with 
significant ventricular wall thickening (parietal thickness equal to or more than 
15 mm) an elevated E/A ratio was observed, suggesting a restrictive cardiomy-
opathy [19, 27]. In late-stage disease the deceleration time is markedly reduced 
(restrictive pattern).
The diastolic function is usually severely impaired, with a restrictive pattern 
defined by a decrease deceleration time on the transmitral pulsed Doppler and low 
tissue Doppler velocities in the left ventricular wall; E/e’ is often higher than 15, 
which suggests elevated filling pressures (Figure 4) [29].
Figure 2. 
2D echocardiogram (apical 4 chamber view and parasternal short axis view) in a patient with AL type 
cardiac amyloidosis revealing increased thickness of the left ventricular walls.
Figure 3. 
2D echocardiogram (apical 2 chamber view, M-mode in parasternal long axis view and apical 4 chamber 
view) in a patient with AL type cardiac amyloidosis revealing increased thickness of the left ventricular walls, 





The speckle-tracking echocardiography (STE) plays a major role in evaluation of 
patients with CA, being a sensitive echocardiographic technique which detects cardiac 
damage due to amyloid infiltration from early stages, even when other classic param-
eters are still in range [30]. In patients with CA, a reduced global longitudinal strain 
can be observed when the left ventricular ejection fraction is still preserved [31].
Speckle tracking imagining in CA reveals reduced longitudinal shortening at the 
basal and mid-ventricular level with preserved longitudinal function at the apex 
[31]. This pattern, described by Phelan et al. as ‘relative apical sparing’ is a helpful 
tool, both sensitive and specific, to make a diagnosis of CA [32]. Longitudinal strain 
bull’s eye plot has a typical pattern that is easy to recognize. The mechanism that 
determines this pattern is not yet clearly understood. Proposed mechanisms include: 
1. a reduced infiltration with amyloid fibrils at the apex, compared to basal segments; 
2. an increased tendency towards apoptosis at basal level, as a result of the higher 
parietal stress [25, 28, 33]. This typical appearance was first described in late-stage 
CA, but there are studies that suggest its presence in less affected hearts [31, 34].
Figure 4. 
2D echocardiogram with tissue Doppler sample at base of the interventricular septum and pulsed-wave 
Doppler at mitral valve inflow in a patient with AL type cardiac amyloidosis revealing impaired relaxation, 
septal e’ of the LV decreased and a pseudonormal pattern.
Figure 5. 
Left ventricular strain image with impaired longitudinal shortening at basal and mid-ventricular level with 
preserved longitudinal function at the apex (relative apical sparing) as seen in the bull’s eye plot on the right.
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Figure 6. 
MRI images: short axis 2D myocardial delayed enhancement (left) and four-chamber 2D myocardial delayed 
enhancement (right): diffuse, inhomogeneous late gadolinium enhancement, suggestive of cardiac amyloidosis.
2D STE is helpful in differentiating the thickness of myocardium caused by amy-
loidosis from a real left ventricular hypertrophy. In CA a systolic septal longitudinal 
base-to-apex strain ratio more than 2.1 in association with a low deceleration time 
is useful to differentiate it from patterns encountered in other types of ventricular 
thickening, such as true hypertrophy (Figure 5) [19, 31].
7. Magnetic resonance imaging in CA
The use of cardiac magnetic resonance (CMR) in patients with CA allows a 
good definition of cardiac morphology, ventricular and valvular function, and the 
possibility to analyze the structure of the ventricular wall [35]. However, the main 
benefit of CMR imaging in this disease remains the evaluation of the ventricular 
diastolic function and the structure of the ventricular wall.
The gadolinium contrast agents are very useful in characterizing the myocardial 
wall structure due to the differences in clearance of gadolinium between normal 
myocardium, edematous or scarred myocardium, and myocardium with amyloid 
deposits.
The gadolinium contrast agents accumulate in extracellular spaces of both 
normal myocardium and diseased one, but it is rapidly washed out from the normal 
areas, remaining in the pathological areas, late after the contrast has washed out 
from the normal tissue. The late gadolinium enhancement (LGE) of the myocar-
dium has different patterns in different diseases, which, together with the other 
functional changes that can be evaluated by MRI. The ischemic scars appear as 
subendocardial LGE in a coronary territory, usually associating the thinning of the 
myocardial wall. In contrast to this, the amyloid deposits appear as subendocardial 
LGE that extend beyond a coronary artery territory (the “arch” shaped LGE) and is 
usually associated with increased wall thickness. In more severe stages the suben-
docardial LGE can be diffuse (the “annular” shaped LGE) or it can even become 
a transmural LGE [36]. These aspects can combine in the same patient, as they 
represent a continuum from no amyloid deposits and no LGE to subendocardial 
LGE and then to diffuse and transmural, intense LGE [37].
The expansion of the extracellular space due to amyloid deposition can also 
be measured by the T1 mapping technique allowing monitoring of the treatment 
response [38]. The extracellular volume (ECV) is below 28% in normal situations 
and can increase significantly with edema and fibrosis, but also with amyloid 
deposition. An increase above 40% of ECV is a highly suggestive sign for amyloi-




appearance [39]. Given the T1 mapping technique which allows objective measure-
ment of the extracellular volume, the response to treatment can be monitored 
(Figure 6) [40].
8. Nuclear medicine: radionuclide scintigraphy
Bone affinity isotope scintigraphy plays an important part in the early diagnosis 
of ATTR-type CA and in its differentiation from AL amyloidosis and other types of 
hypertrophic heart disease [41].
The radiotracers recommended in diagnosing ATTR amyloidosis are: 99 mTc - 
PYP (pyrophosphate), 99mTc - DPD (3,3-diphosphono-1,2-propanodiacarboxylic 
acid) and 99mTc-labeled hydroxymethylene diphosphonate (HMDP) [42]. They 
have an increased affinity for calcium. In ATTR-type amyloidosis, the extracel-
lularly deposited amyloid, at the cardiac level, contains a protein that binds amyloid 
fibers through a calcium-dependent mechanism, which explains the affinity of 
these radiotracers for this type of amyloid [43]. There are comparative studies on 
endomyocardial biopsies, which show that patients with ATTR amyloidosis present 
more frequent microcalcifications in comparison to those with AL amyloidosis. In 
very few cases, however, patients with AL amyloidosis may have microcalcifications 
and in these situations scintigraphy with bone affinity radiotracers may be slightly 
positive [44].
Other radiotracers that can be used to highlight CA and differentiate it from 
other hypertrophic cardiomyopathies are as follows: 11C-Pittsburgh compound B 
(11C-GDP), 18F-florbetaben, and 18F-florbetapir. They have affinity for both the 
AL-type amyloid and ATTR and require further clinical trials for validation [41, 43].
The scintigraphy using the 123I-metaiodobenzylguanidine tracer can also 
detect the sympathetic denervation of the heart and thus patients at risk of cardiac 
arrhythmias can be identified [41, 45].
High levels of light serum and urinary chains or of medullary plasma cells are 
suggestive of AL-type amyloidosis, and biopsy is required to confirm amyloid 
deposits. In this case, myocardial scintigraphy is performed only to obtain addi-
tional information [41].
When monoclonal gammopathy is not present, myocardial scintigraphy with 
bone avidity radiotracers is required. If it reveals abnormal uptake of the radiotracer 
at the myocardial level, the diagnosis of ATTR amyloidosis is made with a sensitiv-
ity of 100%. Biopsy is not required for detecting amyloid deposits [41].
The myocardial scintigraphy protocol with bone affinity radiotracers involves 
monoplane imaging (anterior and posterior), 3 hours after the intravenous admin-
istration of the isotope, which allows the identification of radioactive tracer uptake 
and its quantification by visual evaluation of the Perugini score (0- no uptake, 1 
- low uptake, of subcostal intensity, 2 - significant uptake, of intensity equal to that 
of the ribs, 3 - important uptake, of supracostal intensity) [43, 46].
Another way of assessing the uptake of radiotracer at the level of the heart 
involves performing the ratio between the values measured in a certain region at the 
level of the heart (H) and at the contralateral level (CL), one hour after the admin-
istration of the radiotracer [25, 47].
When the value of the Perugini score is higher than or equal to 2 and/or if the 
value of the H/CL ratio is higher than or equal to 1.5, the diagnosis of ATTR amyloi-
dosis is made [47].
The H/CL ratio also has a prognostic value. Thus, values higher than 1.5 are asso-
ciated with the survival reduction to 5 years (together with the echocardiographic 
characteristics of a more advanced stage of the disease) [43].
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9. Diagnostic strategy in CA
Diagnosis of CA can be difficult given the polymorphic and nonspecific clinical 
manifestations [41] of this systemic disease. CA must be considered in the dif-
ferential diagnosis in HF with left ventricular hypertrophy and preserved ejection 
fraction. By the time of the onset of signs and symptoms, it is essential not to delay 
the diagnosis because it has a negative influence on evolution and prognosis of the 
patient. Below is an algorithm for an easier approach to the diagnosis CA [41, 48, 
49]. Two important steps in this algorithm in patients with clinical suspicion of CA 
are screening for monoclonal protein (for identification of kappa or lambda free 
light chains) and, in case this is positive, biopsy, most of the time from fat pad, 
which has a sensitivity and specificity of 79% and 80% respectively for diagnosing 
amyloidosis (Figure 7) [50].
10. General treatment of heart failure in CA
Therapy of HF along with the treatment of the underlying disease stand for 
different sides of the same coin in CA. There are several dissimilarities regarding 
medications used in CA with HF, compared to those used in patients with non-CA 
HF with reduced ejection fraction (HFrEF). The median survival after the onset of 
HF is less than 6 months in untreated patients [51].
10.1 Medical treatment of heart failure in CA
General treatment management in patients with CA and HF is challenging due 
to lack of randomized clinical trials on which to fundament treatment strategies 
[52]. Therapy should first focus on a sodium restriction diet and daily weight moni-
toring in conjunction with diuretics, in order to improve congestion and relieve 
symptoms. Neurohormonal blockade is recommended by current HF guidelines 
[53, 54] for patients with HFrEF regardless of its etiology, but various concerns have 
been raised in patients with CA-HF due to potential harmful effects [55].
Thus, diuretics and especially loop diuretics in combined with a mineralocorti-
coid receptor antagonist, represent the cornerstone of therapeutic strategies in this 
group of patients [52, 55, 56]. Clinical benefit of other usual HF therapies including 
beta-blockers (BB), calcium channel blockers (CCB) and angiotensin-converting 
enzyme inhibitors (ACEI) has not yet been proven, moreover these therapies may 
even be harmful in CA patients [55, 57, 58].
In amyloid cardiomyopathy, CCB and digitalis are contraindicated because they 
can bind to amyloid fibrils and determine severe adverse effects such as serious 
hypotension and syncope [58, 59]. Moreover, BB and ACEI can cause marked 
hypotension due to low cardiac output and fatigue, leading to a limited tolerability 
among these patients. Orthostatic hypotension caused by autonomic dysfunction 
can be exacerbated by ACEI or angiotensin receptor blockers, and the coexistence 
of renal dysfunction can limit their usage [52, 58]. Still, these medications should be 
cautiously considered in selected cases of severe nephrotic syndrome with marked 
proteinuria [58].
Beta-blockers with their negative chronotropic and inotropic effects, interfere 
with contractility and heart rate which help maintain cardiac output, resulting in 
significant hypotension, extreme bradycardia and even heart block since amyloid 
patients are already predisposed to electrical conduction anomalies [52, 55, 58]. 
However, in case of atrial tachyarrhythmias, BB (particularly in low doses) might 




Overall, authors agree that common medications for subjects with non-amyloid-
HFrEF, should be carefully considered in those with CA-HFrEF [52, 55, 58]. 
Furthermore, these therapies should be discouraged in HF with preserved ejection 
fraction (HFpEF) and CA [56].
10.2 Heart transplantation and ventricular assist devices
Previously, overall heart transplantation in CA was thought to be contrain-
dicated since amyloidosis represents a systemic disease and there is an increased 
risk of relapse [55, 58, 60]. In transplanted amyloid patients compared to standard 
heart transplant patients, there was no difference in survival rate, and those with 
end stage disease continue to have an extremely poor prognosis (50% death on the 
waiting list) [61, 62].
Many authors focused their attention in the last decade on mechanical circula-
tory support (MCS) for end-stage CA. Left ventricular assist device (LVAD), 
biventricular assist device (BiVAD) and total artificial heart (TAH) nowadays 
Figure 7. 
Diagnostic strategy in CA. (ECG, electrocardiography; CMR, cardiovascular magnetic resonance imaging; 
HE, hematoxylin eosin staining; AL, amyloid light-chain amyloidosis; AA, amyloid A protein amyloidosis, 
AApoA1, apolipoprotein AI-derived amyloidosis; MGUS, monoclonal gammopathy of undetermined 
significance; ATTR, transthyretin amyloidosis; ATTRwt, wild-type transthyretin amyloidosis; ATTRv, mutant 
transthyretin amyloidosis).
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represent either bridge to transplantation (BTT) or destination therapies [63–68]. 
Some studies reveal that TAH is a feasible bridging therapy, with 82% survival, and 
should be preferred over LVAD therapy for durable support in selected patients 
[64]. Accordingly, LVAD is not suitable for CA patients with left ventricular end-
diastolic diameter under 46 mm and was even associated with higher mortality 
post-implantation [64, 66]. Other studies found no significant difference in wait-
list and up-to 5-years survival after heart transplantation in subjects sustained by 
BiVAD or TAH as bridging therapies [65, 66]. Outcomes become acceptable with 
advances in specific therapies for the underlying disease and heart transplant or 
heart/liver transplant could even be curative in selected cases, but there is still need 
for additional studies [57, 60].
10.3 Atrial fibrillation and anticoagulation
While AF is the most frequent arrhythmia in HF patients, in amyloid patients, 
traditional therapies could lead to severe side effects and in general, are poorly tolerated 
[18, 53]. Rate and rhythm management among this population continue to be challeng-
ing. For rate management the usage of beta-blockers in low doses may be attempted, but 
their clinical benefit remains unproven in CA. Nondihydropyridine CCB and digoxin 
are not recommended and may even be toxic for these patients [18, 52, 55]. Options for 
pharmacologic rhythm control are restricted, but studies support the use of amiodarone 
as first choice antiarrhythmic therapy, since it tends to be well tolerated [18, 52].
Some experts advise following a rhythm control strategy over a rate control 
strategy in amyloid patients, but there are no studies to support this strategy until 
present days.
Last but not least, several studies concluded that chronic oral anticoagulation is 
recommended in all patients with CA and AF irrespective of CHADS-VASC score 
due to an increased risk of thromboembolic events [55, 57, 69].
10.4 Cardiac implantable electronic devices
Implantable electronic devices such as pacemaker and/or implantable cardio-
verter-defibrillator (ICD) have not been shown to prevent sudden cardiac death 
or improve survival in CA patients [18, 52, 55, 57, 70]. Moreover, since overall 
mortality after implantation outweighs its benefits, cardiac implantable electronic 
devices should be used mainly for secondary prevention (hemodynamic instabil-
ity due to ventricular arrhythmias) in patients with more than a year survival rate 
[52, 54, 55, 57]. However, permanent pacemakers, especially biventricular pacing, 
were shown to improve symptoms and should be considered in patients with CA 
and severe conduction disease [18, 57].
11. Specific treatment of AL amyloidosis cardiomyopathy
The last two decades have brought in a decrease in mortality rates and improved 
survival in patients with AL amyloidosis, mainly due to early diagnosis and better 
treatment implementation [71]. During the same period, new treatment options 
have become available for these complex patients, among which the most notable 
are new chemotherapy regimens, autologous stem cell transplantation, proteasome 
inhibitors and monoclonal antibodies [72].
Treatment should be adapted according to the patient’s comorbidities and sever-





Apart from patients with monoclonal gammopathies of undetermined signifi-
cance (MGUS) or smoldering myeloma, in whom initiation of specific therapy 
could be delayed until the first sign of organ involvement, all patients diagnosed 
with AL amyloidosis should be initiated on specific therapy as soon as possible 
[74, 75].
The treatment of these subjects should be decided by a multidisciplinary team, 
coordinated by a hematologist and with the involvement of other relevant medical 
specialties: nephrology, cardiology, pneumology, neurology and gastroenterol-
ogy [76].
In addition to specific HF therapy, which has several peculiarities compared to 
that of the general population, patients with AL amyloidosis and cardiac involve-
ment require treatment of the underlying disease [77].
The purpose of therapy in cardiac AL amyloidosis is to reduce the serum free 
light-chain levels and to obtain organ response. This should be done promptly and 
for as long as possible, in order to obtain a reduction of more than 90 percent in free 
light-chain levels, therefore preventing further amyloid deposition and fibrillogen-
esis [75, 78].
The standard treatment includes high-dose chemotherapy in combination with 
autologous stem cell transplantation (ASCT), alkylating agents, steroids, protea-
some inhibitors, and immunomodulatory drugs [76]. An adequate level of response 
may not be obtainable in all patients. Because of this, treatment efficacy should 
be assessed at 3 months after ASCT (autologous stem cell transplantation) and 
1–2 months after nontransplantation therapies. A decision to shift to other regimens 
depends on the hematologic response [76]. Patients with important cardiac involve-
ment have a higher mortality despite good initial hematologic response, while a 
rapid improvement of cardiac biomarkers and left ventricular ejection fraction can 
be seen in those with mild CA when free light chain can be significantly reduced 
[73, 75].
Risk stratification is essential when choosing the treatment strategy. Only 20% 
of the patients newly diagnosed with AL amyloidosis are eligible for ASCT, these 
being considered low risk patients. Effective up-front therapy may increase this 
percentage, making certain other patients eligible [78]. Generally, in order to be 
eligible for ASCT, patients should meet the following criteria: age ≤ 70 years, cTnT 
<0.06 ng/mL, NT-proBNP <5000 ng/L, systolic blood pressure ≥ 100 mmHg, LVEF 
>45%, New York Heart Association (NYHA) functional class I or II, creatinine 
clearance ≥50 mL/min (unless on chronic stable dialysis), Eastern Cooperative 
Oncology Group (ECOG) performance status ≤2, DLCO >50%, less than 3 organs 
significantly involved (heart, liver, kidney, or autonomic nervous system) [76, 77].
Treatment with bortezomib, a proteasome inhibitor, should be considered in 
low-risk patients prior to ASCT if there are no contraindications, in order to achieve 
high rates of deep and durable hematologic response. This should be followed by 
high dose melphalan, an alkylating agent, combined with autologous stem cell 
transplantion, rather than chemotherapy alone [78]. ASCT allows the administra-
tion of high doses of melphalan, with myeloablative effect, thus contributing to the 
suppression the underlying plasma cell dyscrasia [79].
As mentioned above, the majority of AL amyloidosis patients are not eligible for 
ASCT, being staged in a class of intermediate or high risk [76]. For these patients, 
the most common initial chemotherapy regimens used nowadays are bortezomib-
based, such as combinations with cyclophosphamide and dexamethasone (CyBorD) 
or melphalan and dexamethasone (BMDex). These regimens have a significantly 
higher hematological response rate, a longer progression-free period and increased 
overall survival compared to the older regimen of dexamethasone and prednisone, 
which has been the standard of care for many years in these subjects [79, 80].
Cardiomyopathy - Disease of the Heart Muscle
14
Daratumumab is an anti-CD38 monoclonal antibody, which has a direct on-
tumor and immunomodulatory mechanism of action, with proven activity in AL 
amyloidosis, which is particularly attractive in case of severe cardiac involvement. 
High risk patients with important cardiac involvement and NYHA class III or IV 
and ECOG PS = 4, need a very rapidly acting and safe regimen and supportive 
therapy during the chemotherapy cycles in order to sustain organ function [81]. 
Recently, in the phase 3 ANDROMEDA-trial, a combination of daratumumab with 
CyBorD in patients with newly diagnosed AL amyloidosis resulted in significantly 
higher hematologic, cardiac, and renal response rates typically within one cycle, 
and was well tolerated. Therefore, it should be considered a promising novel 
therapy for AL amyloidosis [82].
In patients in whom a rapid and significant reduction in the serum free light-
chain levels is not achieved, a second-line treatment should be considered after 
hematological response assessment. In responders, maintenance therapy is not 
indicated [76, 83].
Organ response criteria are essential during treatment follow-up. Cardiac 
biomarkers, especially NT-pro BNP, have a particular importance for the cardiac 
response, although they are influenced by therapy related complications, fluid 
status and supraventricular tachyarrhythmias, very common in CA [84]. A decrease 
with more than 30% and > 300 ng/l, in NT-pro BNP levels and an improvement 
of NYHA functional class has been demonstrated to be associated with increased 
overall survival [83].
In patients resistant to alkylating agents and proteasome inhibitors, immuno-
suppressive therapy is the only remaining option. Treatment regimens that include 
immunosuppressant agents (lenalidomide, thalidomide) have demonstrated 
efficacy among patients with relapsed or resistant AL amyloidosis. These are gener-
ally avoided due to significant cardiac and renal toxicity, and are especially useful in 
patients with contraindications to bortezomib or in subjects with refractory disease. 
Figure 8. 
Treatment algorithm of AL Amyloidosis. CyBorD = cyclophosphamide and dexamethasone; 
ASCT = autologous stem cell transplantation; MDex = melphalan and dexamethasone; 





Treatment with these agents is associated with increased NT-pro BNP levels and 
affects the assessment of cardiac response, Also, worsening of renal failure and 
increased proteinuria can be detected [85, 86].
Low dose thalidomide in addition to cyclophosphamide and dexamethasone 
(CTDa) was demonstrated to have the highest response rates, with acceptable toxic-
ity, but it is not recommended as a routine maintenance therapy due to cumulative 
neurotoxicity [87]. Lenalidomide in combination with low dose dexamethasone, 
with or without cyclophosphamide, could be taken into consideration in patients 
with relapsed AL amyloidosis, but with an increased risk of thrombotic complica-
tions (Figure 8) [88].
12. Specific treatment of ATTR amyloid cardiomyopathy
Recent findings in the research of molecular pathogenic mechanisms revolution-
ized the treatment of ATTR amyloidosis. New agents have recently been developed 
to suppress the production of amyloid in both wild-type and hereditary CA. 
Current treatment strategies include management of underlying disease process in 
association with symptomatic relief.
12.1 Disease modifying therapies
1. TTR synthesis inhibitors target by inhibiting the hepatic synthesis of TTR.
• Patisiran (0.3 mg/kg iv., once daily, every three weeks for 18 months) is a 
second-generation small interfering RNA (siRNA), which blocks the expres-
sion of TTR, leading to reduction in TTR levels [89].
• Inotersen (200 mg sc., once a week) is a second-generation antisense oli-
gonucleotide, which lowers hepatic production of TTR by bonding to the 
mRNA [89].
Both these drugs lead to a reduction of >85% in the concentration of circulat-
ing TTR. Two recent randomized trials have demonstrated reduction in the 
progression of polyneuropathy in patients with ATTRv: the APOLLO trial 
[90]. (The Study of an Investigational Drug, Patisiran, for the Treatment of 
TTR Amyloidosis) and the NEURO-TTR [91]. trial (Efficacy and Safety of 
Inotersen in Familial Amyloid Polyneuropathy). Even though not explicitly 
tested, TTR synthesis inhibitors may have beneficial cardiac effects [91, 92]. 
In order to demonstrate cardiac benefits, two clinical trials assessing the ef-
ficacy of TTR synthesis inhibitors in patients with cardiomyopathy are cur-
rently ongoing: 24 Month Open Label Study in the Tolerability and Efficacy of 
Inotersen in TTR Amyloid Cardiomyopathy Patients and the APOLLO-B trial 
(A Study to Evaluate Patisiran in Participants With TTR Amyloidosis With 
Cardiomyopathy).
2. TTR stabilizers prevent the misfolding of TTR by binding to TTR tetramer.
• Tafamidis slows the dissociation of TTR tetramers into monomers by 
binding to the thyroxine-binding site of the TTR. In the ATTR-ACR 
randomized trial (Safety and Efficacy of Tafamidis in Patients with TTR 
Cardiomyopathy), which recruited both patients with ATTRv cardiomy-
opathy and ATTRwt cardiomyopathy, there was a significant lower all-cause 
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mortality and cardiovascular-related hospitalization after 30 months after 
receiving Tafamidis when compared to placebo. Moreover, there was a lower 
rate of decline in the 6-minute walk test and in the quality of life under both 
Tafamidis doses (20 and 80 mg orally) [93]. Tafamidis was approved for the 
use in TTR cardiomyopathy in May 2019.
• Diflunisal is a non-steroidal anti-inflammatory drug, which significantly 
reduced the progression of polyneuropathy by stabilizing TTR tertramers in 
a randomized trial [94]. Although no controlled trials evaluated the effect of 
Diflunisal on TTR cardiomyopathy, two single center studies demonstrated 
some benefits (250 mg orally twice daily) [95, 96]. However, side effects are 
not rare (thrombocytopenia and renal dysfunction), administration should 
be avoided in patients with eGFR<45 mL/min/1.73m2, thrombocytopenia or 
signs of hemodynamic or renal instability [97]. Diflunisal is not approved for 
TTR amyloidosis and can be used off-label.
• AG10 is a synthetic TTR ligand, which acts by binding to the TTR tetramer 
and therefore prevents amyloid fibril formation and deposition. A phase II 
randomized multicenter study demonstrated that AG10 (400 mg or 800 mg 
twice daily for 28 days) induced almost complete stabilization of TTR and 
patients treated with AG10 showed reduced mortality and cardiovascular 
hospitalization at 15 months [97].
• Tolcapone is approved for the treatment of Parkinson disease and acts by 
inhibiting TTR aggregation. It is currently under investigation in patients 
with TTR amyloidosis [55].
3. TTR disruptors target the clearance of amyloid fibrils from tissue.
• The combination of Doxycycline and TUDCA (tauroursodeoxycholic 
acid) removed amyloid deposits in preclinical studies, but there was a high 
incidence of side effects [98, 99]. The role of these therapies is therefore 
uncertain.
12.2 Symptomatic relief
The control of peripheral and autonomic neuropathy leads to significant 
improvement in the quality of life. Implantation of a cardiac pacemaker might 
be beneficial in patients with TTRv and conduction disorders [100]. Implantable 
cardioverter-defibrillators (ICD) are recommended in patients with significant 
arrhythmias or aborted sudden cardiac death with expected survival of more than 
one year. Although reduction in cardiac filling pressures is also necessary, it must be 
performed with caution, as these patients are dependent of the cardiac output. On 
the same principle, many drugs used in the treatment of HF might not be beneficial 
in patients with CA and some agents might have an abnormal distribution by bind-
ing to amyloid fibrils (eg. digoxin) [100].
12.3 Management of TTR amyloidosis in patients with aortic stenosis
Recent data demonstrated that the association between CA and aortic stenosis 
(AS) is more common than previously known and TTR cardiac amyloidosis is the 




evaluate the best therapeutic management in patients with TTR cardiac amyloidosis 
and AS, the treatment of CA follows the general principles and should be instituted 
immediately after the diagnosis is confirmed. Regarding the management of AS, the 
majority of the studies reported a high risk of mortality after surgical aortic valve 
replacement (SAVR) [101–106].
One study performed on a limited number of patients demonstrated that in 
patients with CA and AS outcomes might be better with trans-aortic valve replace-
ment (TAVR) than SAVR [102]. Two ongoing prospective trials, ATTRact-AS (The 
Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis) and Amylo-
CARTESIAN (Prevalence and Post-surgical Outcomes of CARdiac Wild-type 
TransthyrEtin amyloidoSIs in Elderly Patients With Aortic stenosis Referred for 
Valvular Replacement) might lead to better understanding of the prevalence and 
management of patients who present both pathologies. One recently published 
sub-study of the ATTRact-AS trial showed that there was no difference in mortality 
after TAVR between patients with CA and AS or AS alone [107]. Thus, TAVR might 
be a better option for patients with intermediate to high surgical risk. However, 
since some patients might be prone to complications during TAVR because of the 
fragility of the infiltrated myocardium [108]. a multidisciplinary heart team should 
discuss the optimal therapy.
13. Summary
Amyloidosis represents a heterogeneous group of disorders that present as 
a multi-organ disease presenting with unspecific symptoms. The diagnosis of 
amyloidosis often is difficult and can be delayed, and therefore the number of 
unreported cases is likely quite significant.
Amyloid can infiltrate all structures of the heart including ventricular and atrial 
walls, the conduction system, the heart valves, and the coronaries. The typical 
clinical presentation in CA is that of a restrictive cardiomyopathy. When present, 
cardiac amyloidosis has a significant impact on disease prognosis.
Cardiac biomarkers, echocardiography, and other imaging techniques such as 
CMR or 99mTc-phosphate scintigraphy are available for the diagnosis of CA as well 
as determination of the extent of this disease. Endomyocardial biopsy remains the 
main method used for histopathological confirmation and subtyping of CA.
The main goal of the diagnostic strategy is to detect CA early, to define the 
extent of CA, and to enable targeted therapy.
14. Conclusion
Until recently, amyloidosis was still considered a rare multi-organ disease. The 
diagnosis of CA was often missed or only documented at a late stage with negative 
impact on the prognosis of the patients.
Meanwhile, it has become evident that CA is more prevalent than once thought 
and can be the only manifestation of amyloidosis so that early diagnosis and subse-
quent therapy are becoming increasingly important.
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